The Enron Discount
Executive Summary
Transparent number-crunching is back in vogue. Companies that pursue obfuscating accounting strategies to finesse their bottom line may suffer from a new form of ED: the Enron Discount. But so long as the investment community is clamoring for a simple answer (earnings growth) to the complex question of a company's fiscal health, companies will continue to use whatever GAAP-approved means is necessary to appease.
You may also be interested in...
Dealmaking on a Small Planet: Medical Device Transactions 2001
Dealmaking in the device industry is occasional and incremental when compared with the level of activity in pharmaceuticals, the result of that industry's maturing into a handful of dominant players, not all of which see acquisitions as strategically critical to their long-term success. The less-than-robust public market for small device companies is both symptom and cause of the device dealmaking lull. Because the markets they target are generally too small to sustain years of significant growth, few investors are willing to invest in them as stand-alone companies. And without long-term investor support, smaller firms have few options other than to sell out to large companies and little negotiating leverage when they do so.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.